Company: PTHS
Filing Date: 2025-03-27
Form Type: 10-K
Source: 0001753926-25-000503
Chunk: 2141

Company: Pelthos Therapeutics Inc.
Filing Date: 2025-03-27
Form: 10-K
Item: Item 11
Chunk 2141
---
 into a material related-person transaction with us without the review and approval of our
audit committee, or a committee composed solely of independent directors in the event it is inappropriate for our audit committee
to review such transaction due to a conflict of interest. Such policy provides that any request for us to enter into a transaction
with an executive officer, director, nominee for election as a director, beneficial owner of more than 5% of our Common Stock
or with any of their immediate family members or affiliates, in which the amount involved exceeds the lesser of (i) $120,000 or
(ii) one percent of the average of the Company’s total assets at year-end for the last two fiscal years, will be presented
to our audit committee for review, consideration and approval. In approving or rejecting any such proposal, we expect that our
audit committee will consider the relevant facts and circumstances available and deemed relevant to the audit committee, including,
but not limited to, whether the transaction is on terms no less favorable than terms generally available to an unaffiliated third
party under the same or similar circumstances and the extent of the related person’s interest in the transaction.

Item
14. Principal Accountant Fees and Services.

Marcum
LLP is our independent registered public accounting firm and performed the audits of our consolidated financial statements for
the years ended December 31, 2024 and 2023. The following table sets forth all fees billed or to be billed for such periods:

    2024  
    2023 

    Audit fees (1) 
    $211,817  
    $164,229 

    Audit-related fees (2) 
     82,546  
     156,346 

    Tax fees (3) 
     —  
     — 

    All other fees (4) 
     77,092  
     43,490 

    Total 
    $371,455  
    $364,065 

(1)
“Audit fees” include fees for professional services rendered in connection with the audit of our annual consolidated
financial statements, review of our quarterly condensed consolidated financial statements and advisory services on accounting
matters that were addressed during the annual audit and quarterly review. This category also includes fees for services that were
incurred in connection with statutory and regulatory filings or engagements, such as consents and review of documents filed with
the SEC.

102 

(2)
“Audit-related fees” include